COVID-19, Oncology Dominate Korea’s Fast-Track Approval Program
New Breakthrough Therapy Scheme
The number of approvals under a South Korean fast-track scheme launched around two years ago has increased, led more recently by COVID-19 vaccines and treatments, as well as anticancer drugs. Meanwhile, a new breakthrough therapy program similar to that in the US has been introduced to prioritize and speed up regulatory reviews of innovative medicines.
You may also be interested in...
Several innovation-based Korean bioventures, including GI Innovation, S.Biomedics and Curocell, have managed to launch IPOs in 2023 despite prolonged depressed market sentiment and tougher stock exchange rules.
A policy report by a major South Korean pharma industry association puts forward suggestions on what it will take for a new pan-government control tower to function properly.
At the recent World Bio Summit in Seoul, global health leaders discussed international cooperation strategies and policies to prepare for the next pandemic, with a focus on rapid vaccine development.